Invention Application
US20160317626A1 Lysosomal Phospholipase A2 (LPLA2) Activity as a Diagnostic and Therapeutic Target for Identifying and Treating Systemic Lupus Erythematosus
审中-公开
溶酶体磷脂酶A2（LPLA2）作为鉴定和治疗系统性红斑狼疮的诊断和治疗靶标的活性
- Patent Title: Lysosomal Phospholipase A2 (LPLA2) Activity as a Diagnostic and Therapeutic Target for Identifying and Treating Systemic Lupus Erythematosus
- Patent Title (中): 溶酶体磷脂酶A2（LPLA2）作为鉴定和治疗系统性红斑狼疮的诊断和治疗靶标的活性
-
Application No.: US15095685Application Date: 2016-04-11
-
Publication No.: US20160317626A1Publication Date: 2016-11-03
- Inventor: James A. Shayman , Akira Abe , Robert Kelly , Jessica Kollmeyer , Ye Lu
- Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
- Main IPC: A61K38/45
- IPC: A61K38/45 ; G01N33/68
Abstract:
The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
Public/Granted literature
- US10111937B2 Method of reducing accumulation of intracellular tingible body macrophages Public/Granted day:2018-10-30
Information query
IPC分类:
